Skip to main content

Erica L. Jackson, Ph.D.

Executive Vice President, Target Biology

Dr. Jackson has been Scorpion Therapeutics’ Executive Vice President of Target Biology since October 2020. Prior to joining the company, Dr. Jackson was Senior Director of Tumor Dependencies and Oncology…

Dr. Jackson has been Scorpion Therapeutics’ Executive Vice President of Target Biology since October 2020. Prior to joining the company, Dr. Jackson was Senior Director of Tumor Dependencies and Oncology Discovery at AbbVie Inc. (“AbbVie”) (NYSE: ABBV), formerly Pharmacyclics, between September 2018 and October 2020. Prior to joining AbbVie, she was Head of Biology and Pharmacyclics between 2018 and 2020 and led the biology and in vivo pharmacology programs as Director of Biology at ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) between 2016 and 2018.
Dr. Jackson holds a Bachelor’s Degree in Biology from Brandeis University and earned her Ph.D. in Biology from the Massachusetts Institute of Technology.